Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pseudotyped oncolytic viral delivery of therapeutic polypeptides

An oncolytic virus and therapeutic technology, applied in the field of pseudotyped oncolytic virus delivery of therapeutic polypeptides, can solve the problem of suboptimal anti-tumor efficacy

Inactive Publication Date: 2019-07-05
ONCORUS INC
View PDF81 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the anti-tumor efficacy of the bispecific antibodies, CARs and oncolytic viruses is suboptimal, indicating a continuing need for further development of oncology, antibody and oncolytic virus therapies

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pseudotyped oncolytic viral delivery of therapeutic polypeptides
  • Pseudotyped oncolytic viral delivery of therapeutic polypeptides
  • Pseudotyped oncolytic viral delivery of therapeutic polypeptides

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0361]Example 1: Preparation of pseudotyped VSV-G

[0362] The following protocol was used to prepare an exemplary pseudotyped VSV-G by combining VSV-glycoprotein (VSV-GP) with HIV1-gag and rev proteins.

[0363] Cell culture and transfection: DNA from the following packaging plasmids was mixed and prepared for transfection into 293T cells: pMDLg / pRRE expressing HIV-1 GAG / POL; pRSV / REV expressing HIV-1 REV; and pMD2.G 5 60 5.8 VSV glycoproteins. Add the DNA mixture to 500 μL of pre-warmed Optimem II medium. Prepare a working stock of polyethyleneimine transfection reagent (PEI) at 1 μg / μL in 1xPBS (pH 4.5) and add 88 μL of the working stock to the mixture, maintaining a 4:1 v / w ratio of PEI:DNA . The mixture was vortexed briefly and left at room temperature for 5-10 minutes to form the PEI:DNA transfection complex. Will add up to 2.5x 10 6 Low passage (less than P20) 293T cells were seeded per 15 cm dish in 15 mL of DMEM supplemented with 10% serum and 1% Pen / Strep. Two ...

Embodiment 2

[0365] Example 2: Construction of pseudotyped VSV-G expressing CD28-CA125 bispecific antibody adapter molecule

[0366] Pseudotyped VSV-G was prepared as described in Example 1 and further processed to express nucleic acid encoding an adapter polypeptide comprising an activation domain comprising an anti-CD28 molecule and an antigen recognition domain comprising an anti-CA125 molecule , and a nucleic acid encoding an anti-PD1 immunomodulatory peptide. The resulting oncolytic virus was a pseudotyped oncolytic VSV-G virus encoding a CD28-CA125 adapter molecule and an anti-PD1 therapeutic molecule (CD28-CA125-PD1 VSV-G).

Embodiment 3

[0367] Example 3: CD28-CA125-PD1 VSV-G activates human T cells and exhibits antitumor activity

[0368] Human T cells were infected with pseudotyped CD28-CA125-PD1 VSV-G virus. Between 24 and 48 hours after viral infection, T cell culture media were collected and examined for the presence of pro-inflammatory cytokines. These results will show that T cells are activated by CD28-CA125-PD1 VSV-G, as shown by the presence of pro-inflammatory cytokines such as IFN-β and Evidenced by IL-2.

[0369] EphA2-overexpressing gastric cancer cells from the KATO3 cell line were infected with pseudotyped CD28-CA125-PD1 VSV-G or non-pseudotyped CD28-CA125-PD1 VSV virus, and cell proliferation was assessed. These results will show that cell proliferation is significantly reduced in KATO3 cells infected with pseudotyped CD28-CA125-PD1 VSV-G compared to KATO3 cells infected with non-pseudotyped CD28-CA125-PD1 VSV virus.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Described herein are pseudotyped oncolytic viruses comprising nucleic acids encoding an engager molecule. In some embodiments, the pseudotyped oncolytic viruses comprises nucleic acids encoding an engager molecule and one or more therapeutic molecules. Pharmaceutical compositions containing the pseudotyped oncolytic virus and methods of treating cancer using the pseudotyped oncolytic viruses are further provided herein.

Description

[0001] References to related applications [0002] This application claims priority to US Provisional Application No. 62 / 357,195, filed June 30, 2016, the contents of which are incorporated herein by reference in their entirety. [0003] Instructions for text files submitted electronically [0004] The contents of the text file submitted electronically herewith in its entirety are hereby incorporated by reference in their entirety: Copy of Sequence Listing in Computer Readable Format (File Name: ONCR_004_02WO_ST25.txt; Date of Record: June 30, 2017; File Size: 193 kilobytes). [0005] Background of the invention [0006] Patients with certain blood cancers and solid tumors still need new treatments. The use of bispecific antibodies to direct cytotoxic T cells to tumor cells and the use of chimeric antigen receptors (CARs) to specifically engineer antigens onto immune effector cells have been shown to provide therapeutic benefit. Furthermore, oncolytic virus technology is a u...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N7/01A61K35/768A61P35/00
CPCA61K35/76C07K16/2803C07K16/2809C07K16/2827C07K16/3092A61K2039/507C07K2317/31C07K2317/76C07K2319/03C07K14/522C07K14/5434C07K14/5443C07K14/4703C07K2319/00C12N15/86C12N2740/16032C12N2740/16043C07K16/2818A61K35/768C07K14/70503C07K14/7051C07K14/70532C07K14/70596C07K2319/30C12N9/6491A61P35/00A61P35/02A61P37/02A61P37/04C12N2710/16641C12N2710/16633A61K39/0011C12N7/00C12N2760/20232C12N2760/20243Y02A50/30
Inventor 卢克·叶夫宁
Owner ONCORUS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com